Government-Owned Inventions; Availability for Licensing, 5346 [E6-1286]
Download as PDF
<![CDATA[
5346
Federal Register / Vol. 71, No. 21 / Wednesday, February 1, 2006 / Notices
affects up to twenty percent (20%) of
women during their reproductive years.
Endometriosis is characterized by the
growth of endometrial tissue outside the
uterus. This growth of tissue causes
recurring severe pain and can lead to
infertility. As the current procedure
used for diagnosis is invasive and not
entirely accurate, there is a need for a
fast, accurate, and minimally invasive
test to test for endometriosis.
Using DNA microarray analysis of
blood lymphocytes, the inventors have
identified two gene markers expressed
in blood that are able to discriminate
between those women who have
endometriosis and those that don’t. This
new technology would be minimally
invasive and quick using a blood sample
from a patient.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: January 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–1277 Filed 1–31–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
cchase on PROD1PC60 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
VerDate Aug<31>2005
17:49 Jan 31, 2006
Jkt 208001
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Rapid Anti-Depressant Response
Produced by Low Dose Treatment with
Anti-Muscarinic Drugs
Maura Furey and Wayne Drevets
(NIMH).
U.S. Patent Application No. 11/137,114
filed 25 May 2005 (HHS Reference
No. E–175–2004/0–US–01).
Licensing Contact: Norbert Pontzer; 301/
435–5502; pontzern@mail.nih.gov.
Available for licensing are new
methods of rapidly treating depression.
The drugs currently used to treat
depression work by increasing the
activity at serotonin, norepinephrine
and perhaps dopamine receptors in the
CNS. However these drugs are effective
in only 60–70% of patients, require 3–
4 weeks of treatment before clinical
improvement and have many side
effects. These inventors have shown that
in human patients, the administration of
anti-muscarinic agents produces a rapid,
prolonged alleviation of depressive
symptoms. Beginning the day following
administration of the anti-muscarinic
agent, a majority of patients show
significant improvements in mood,
anxiety, sleep and other depressive
symptoms that last days or weeks. The
very slow dissociation of some
muscarinic agents from their receptors
may account for the prolonged
therapeutic effects.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: January 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–1286 Filed 1–31–06; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
State-of-the-Science Conference:
Cesarean Delivery on Maternal
Request; Notice
Notice is hereby given of the National
Institutes of Health (NIH) ‘‘State-of-theScience Conference: Cesarean Delivery
on Maternal Request’’ to be held March
27–29, 2006, in the NIH Natcher
Conference Center, 45 Center Drive,
Bethesda, Maryland 20892. The
conference will begin at 8:30 a.m. on
March 27 and 28, and at 9 a.m. on
March 29, and will be open to the
public.
Despite the national goal of reducing
rates of cesarean delivery to 15 percent
of births established as part of Healthy
People 2010, cesarean delivery rates
have continued to increase. In 2003, 1.1
million or 27.5 percent of births in the
U.S. were by cesarean delivery. An
estimated 2.5 percent of births that year
were cesarean deliveries performed on
request, in the absence of medical
necessity, and the rate of cesareans on
request appears to be growing rapidly
over time.
The potential benefits of elective
cesarean delivery as compared to
vaginal delivery are not fully
understood but are thought to include
decreased risk of urinary incontinence,
pelvic organ prolapse, anal sphincter
damage and fecal incontinence. Elective
cesarean delivery also has the benefit of
flexible timing for mother and
physician. However, like any major
surgical procedure, there are risks
associated with cesarean delivery. Risks
that are known to be higher for cesarean
deliveries than for vaginal delivery
include adverse reactions to anesthesia,
breathing problems, bleeding, infection,
urinary tract injury, and injury to the
baby. In addition, recovery time
following cesarean delivery is typically
longer than for vaginal delivery.
Given these risks, any decision to
deliver by cesarean delivery when
vaginal delivery is also available should
be informed by the best possible
information regarding potential health
outcomes, good and bad, for both
mother and baby. Toward that end, the
National Institute of Child Health and
Human Development and the Office of
Medical Applications of Research of the
National Institutes of Health will
convene a State-of-the-Science
Conference from March 27 to 29, 2006,
to assess the available scientific
evidence relevant to the following
questions:
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 71, Number 21 (Wednesday, February 1, 2006)]
[Notices]
[Page 5346]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-1286]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Rapid Anti-Depressant Response Produced by Low Dose Treatment with
Anti-Muscarinic Drugs
Maura Furey and Wayne Drevets (NIMH).
U.S. Patent Application No. 11/137,114 filed 25 May 2005 (HHS Reference
No. E-175-2004/0-US-01).
Licensing Contact: Norbert Pontzer; 301/435-5502;
pontzern@mail.nih.gov.
Available for licensing are new methods of rapidly treating
depression. The drugs currently used to treat depression work by
increasing the activity at serotonin, norepinephrine and perhaps
dopamine receptors in the CNS. However these drugs are effective in
only 60-70% of patients, require 3-4 weeks of treatment before clinical
improvement and have many side effects. These inventors have shown that
in human patients, the administration of anti-muscarinic agents
produces a rapid, prolonged alleviation of depressive symptoms.
Beginning the day following administration of the anti-muscarinic
agent, a majority of patients show significant improvements in mood,
anxiety, sleep and other depressive symptoms that last days or weeks.
The very slow dissociation of some muscarinic agents from their
receptors may account for the prolonged therapeutic effects.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Dated: January 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-1286 Filed 1-31-06; 8:45 am]
BILLING CODE 4140-01-P
